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Abstract The computational chemistry and cheminfor-
matics community faces many challenges to advancing the
state of the art. We discuss three of those challenges here:
accurately estimating the contribution of entropy to ligand
binding; reliably estimating the uncertainties in model
predictions for new molecules; and being able to effec-
tively curate the ever-expanding literature and commercial
databases needed to build new models.
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Introduction
The road to predicting future scientiﬁc and technological
developments is paved with spectacular failures and
memorable epigrams. Niels Bohr, for example, was fond of
saying, ‘‘Prediction is very difﬁcult, especially about the
future.’’ It is also a corollary of Albert Einstein’s quip that,
‘‘If we knew what it was we were doing, it would not be
called research, would it?’’ Among the most celebrated
examples of erroneous predictions are that ﬂying cars and
personal jetpacks would be common-place by now [1, 2].
The 25th anniversary of an event as notable as the launch
of the Journal of Computer-Aided Drug Design (JCAMD)
compels us to look ahead nonetheless, uncertain though our
vision might be. Fortunately, it is a testament to human
nature that the direction taken by a scientiﬁc discipline is
generally foreshadowed by where the barriers to its pro-
gress lie. Here we discuss three of those barriers—under-
standing the role of entropy in ligand binding, dealing with
predictive uncertainty and the difﬁculty of curating large
amounts of data—in hopes that doing so will provide some
indication of where the ﬁeld might be headed in the next
25 years. Our goal here is mainly to raise questions; pro-
viding answers to those questions remains for those who
come after.
Entropy
When JCAMD began publication, it was easy to believe
that understanding ligand–protein interactions was pri-
marily a matter of running sophisticated and long enough
molecular dynamics simulations on powerful enough
hardware, constrained only by limits on patience and
resources. It was no accident that three of the early land-
mark papers on scoring functions appeared in the journal in
the mid-1990’s [3–5]. The goal of predicting afﬁnity from
ligand and protein structure on a purely mechanistic basis
seems less attainable today, though. Empirical methods are
often competitive with or superior to mechanistic ones
when it comes to predicting afﬁnity within chemical series.
In some cases and in the hands of some practitioners,
empirical methods are superior, as are some empirical
ligand-based methods that ignore the structure of the target
protein altogether and are completely empirical in nature.
Indeed, the inventor of comparative molecular ﬁeld anal-
ysis (CoMFA)—arguably the archetypal mechanistic
modeling approach for ligands—now advocates topomeric
alignments that abandon any pretense of relying on realistic
ligand conformations [6].
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mechanistic models is limited by the inherent difﬁculty of
docking a ﬂexible ligand accurately into a ﬂexible protein
target [7], but supplanting a rigid lock and key model of
ligand–protein interaction with one involving induced ﬁt
begs a fundamental question: if the protein is in a lower-
energy state before the ligand inserts itself into the active
site than it is after, then where does the extra energy needed
to ‘‘turn the key’’ and change the shape of the lock after
binding come from? For the process to be spontaneous,
there must be a net decrease in free energy (DG) above and
beyond that gained by the initial insertion of the ligand into
the unoccupied binding site.
Somewhat counterintuitively, a major positive contributor
to the entropy of binding (DS) is increased protein ﬂuidity
afteraligandbinds—inparticular,anincreaseinanharmonic,
coupled motions within the complex [8–10]. The coupling is
presumably mediated at least in part by polar interactions
between residues, which may contribute to the apparent
ubiquityofenthalpy-entropycompensationinligandbinding.
Theresultingentanglementofenthalpyandentropyis,inturn,
consistentwithrecentanalysisofisothermalcalorimetricdata
for ligand–protein complexes for which high-resolution
complexes are available, work which underscores just how
tightlyDS is connected to the enthalpy ofbinding (DH):Tang
and Marshall [11] showed that the residual error in models of
the total free energy of formation (DG) for such complexes is
lower than the residual error in models of its DHa n d- T DS
components (T is the absolute temperature).
The scope of the challenge of fully accounting for the
afﬁnity of a protein for a ligand based on a static structure
of their complex is underscored by the huge difference in
stability observed between complexes of time-dependent
and time-independent inhibitors with prostaglandin H2
synthase (COX-1). Time-independent binding is fast and
readily reversible, whereas time-dependent binding
involves a subsequent slow step (minutes) and is nearly
irreversible. Nonetheless, X-ray analysis of the complexes
shows that the ligands adopt similar conformations and the
enzyme adopts ‘‘identical’’ conformations [12]. It would
seem that some sort of dynamic effect must account for the
differences between the two, and the sort of anharmonic
ﬂuidity cited above is a prime candidate. Accounting for
such dynamic contributions to DS is complicated, however,
by their fractal nature (at least in the case of myoglobin,
lysozyme and bovine pancreatic trypsin inhibitor) [13],
which suggests that they are chaotic or emergent properties
of complex systems [14]. If that is true in general, the
dynamic contributions will be difﬁcult to deal with using
existing mechanistic methodology. Appreciating the cha-
otic nature of the interaction could, however, help molec-
ular designers understand what makes slow, tight-binding
(‘‘time dependent’’) inhibitors special.
Uncertainty
Regression models of all types have historically been
characterized in terms of how well they ﬁt the data upon
which they are based, usually by the root mean square error
(RMSE), where ‘‘error’’ corresponds to the difference
between the observed and predicted response. Prospec-
tively estimating how much the predicted response for a
new point in the model’s descriptor space is likely to
deviate from the observed response—the predictive
uncertainty—has proven far more difﬁcult. If a model is
based on linear regression and the descriptors are statisti-
cally independent variables, classical statistical theory
provides tools for calculating how large the deviation from
prediction is expected to be for a new observation.
Unfortunately, those tools are inadequate when the model
is non-linear or the descriptors are correlated, and one of
those conditions almost always holds when drug molecules
and biological responses are involved.
The desire for a quantitative estimate of predictive
uncertainty is not diminished simply because statistical
theory fails to provide rigorous tools for providing one,
however. Until fairly recently, the only way this need was
addressed in quantitative structure–activity relationship
(QSAR) analysis was a pragmatic one in which a test set
was held back from the model building process and the root
mean square error of prediction (RMSEP) was calculated
across the compounds in the test set. The QSAR commu-
nity has recently come to realize that this approach is
inadequate when the compound for which a prediction is
desired differs too greatly from the compounds in the
training set used to build a model or the test set used to
evaluate its predictive reliability. That realization has led to
the deﬁnition of ‘‘applicability domains,’’ ranges of
descriptors (or, in a few cases, combinations of descriptors)
outside of which a model cannot be relied upon to accu-
rately predict responses or properties. The need for a
speciﬁed and well-deﬁned applicability domain has even
moved into the regulatory realm, at least in Europe [15].
Unfortunately, the need to establish explicit measures of
predictive reliability has yet to penetrate mechanistic
approaches to activity prediction, i.e., ‘‘structure-based’’
molecular design. Perhaps it goes without saying that the
absence of appropriate force ﬁeld parameters for a silicon
atom would compromise the predictions produced by a
mechanistically based docking program. There also seems
to be an implicit assumption in the ﬁeld, however, that
exactly how a given set of carbon, hydrogen, nitrogen,
oxygen, sulfur, phosphorous and halogen atoms are
assembled to form a new compound is at most incidental to
predictive success, and that aggregate measures of retro-
spective performance on test sets are all that is needed. At
the extremes this is clearly an absurd assumption,
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at all. It is unlikely that a program trained solely on pro-
teases will accurately dock a steroid into the estrogen
receptor, for example, or that a program that has never
‘‘seen’’ a sulfonamide will handle one correctly.
One response to these concerns is that the current pool
of known structures for ligand–protein complexes is now
so large that it represents a broad enough (albeit markedly
biased) sampling of biochemically relevant space that
addition of a few new chemical classes or new targets is
unlikely to affect the overall performance signiﬁcantly.
Even were this so, it overlooks the point that the value of a
prediction is a direct function of the novelty of the structure
for which the prediction is being made, regardless of
whether the ‘‘value’’ in question is social or commercial.
Hence, the predictive uncertainty at the edge of the training
and test set space is more relevant than the average
uncertainty across the entire retrospective structural space.
This is one reason that many in industry are turning to
rolling tests sets—blocks of compounds assayed since the
model was built—to assess the predictive performance of
models. The synthetic culture and target areas of interest at
a company change over time but they do so fairly slowly,
so the compounds made in the last 3 months tend to be
different than those made a year ago; not enormously so,
but enough that some will lie at the edge of the historical
applicability domain. This approach also helps address the
point that there may be some combinations of descriptors
that are relevant for new chemistry but which were inad-
equately explored in the training and test sets.
The ultimate goal should be making reliable predictive
uncertainty estimates for individual new compounds. Some
exploratory work has already been done in this area uti-
lizing sampling and the variance of ensemble predictions
[16, 17], but more is sorely needed if modeling is going to
remain relevant to drug discovery. Most of what has been
done to date assumes (explicitly or implicitly) that the
more similar a candidate molecule is to a molecule from
the training set, the smaller the uncertainty in the prediction
will be, or that the uncertainty in the prediction is directly
related to the prediction errors of training (or test set)
molecules that are ‘‘similar’’ to the candidate molecule.
The exact meaning of ‘‘molecular similarity’’ can be very
sensitive to context however. Molecular similarity, like
beauty, is in the eye of the beholder, and the key beholder
in this case is a target receptor, not a medicinal chemist and
not a computer model.
All similarity-based approaches are prone to failure
when presented with what might aptly be called a ‘‘phan-
tom variable.’’ Consider, for example, the case of a protein
like the PepT1 transporter, which has a strong preference
for binding di- and tri-peptides composed entirely of
L amino acids (‘‘L-peptides’’) over peptides that include one
or more D amino acid residues; enantiomeric peptides
composed entirely of D amino acids (‘‘D-peptides’’) bind
even less well [18]. Hence a 2D QSAR model built using
data only for L-peptides is unlikely to correctly predict the
behavior of D-peptides. The model will ‘‘see’’ a D-peptide
as being within its applicability domain if the enantiomer
is, however, and will predict it with conﬁdence just as high
(or low) as for the corresponding L-peptide. The same holds
true if similarity is based on ‘‘independent’’ descriptors not
used to build the model. Fingerprint-based measures of
similarity, for example, might place a new D-peptide within
the applicability domain of the model, but the transporter is
likely to see the situation differently. Nor is the problem
limited to 2D QSAR; it extends to 3D methods as well.
There will almost always be something that distinguishes a
given new candidate molecule from the molecules in the
training set, and the target may turn out to be sensitive to
that difference. Just this sort of situation doubtless accounts
for some of the activity cliffs that have received so much
attention in the recent literature [19–21]. The problem is
further exacerbated for applicability domains by the need
to use many descriptors to model target properties for very
large data sets. The more descriptors are used, the greater is
the likelihood that a candidate molecule will fall outside
the limits of one or more of these descriptors—the ‘‘curse
of dimensionality.’’ This is the reverse of the (reasonable)
expectation that the larger the training set, the larger a
model’s applicability domain should be! It would seem that
some measure of molecular similarity that is sensitive to
context is needed, as well as recognition that the descrip-
tors needed to construct a model may not always provide
enough information to reliably estimate that model’s pre-
dictive uncertainty for all new candidates.
Curating oceans of data
The rapid increase in computing power since 1986, coupled
with the ease of access provided by the World Wide Web
and digitization of data sources, has made it easier than
ever before to quickly obtain information on an enormous
range of topics. Indeed, the authors drew heavily on
Internet resources to put together this paper. That data is
spread thin, however, in the sense that any single primary
source generally contains only a few items relevant to any
particular topic. The task of pulling dispersed data together
once fell to people who wrote review articles. In many
areas, that function has been supplanted by databases
generated using computer programs. Unlike the authors of
review articles—unlike the conscientious authors, at any
rate—databases generated by unsupervised search pro-
grams tend to agglomerate data rather indiscriminately.
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its nature, derivative. In many cases, it has been copied
over several times since its original abstraction from some
primary source. This makes the potential for rapid and
broad dissemination of errors enormous. The lack of dis-
crimination involved in automated database construction
may be a virtue when it preserves data that might not ﬁt
neatly into a human reviewer’s preconceptions or might
evade their notice, but it becomes a vice when erroneous
data fails to be recognized and labeled as such.
The structure of gallamine triethiodide is a good illus-
trative example where many major databases ended up
containing the same mistaken datum. Until mid-2011,
anyone relying on an internet search would have errone-
ously concluded that gallamine triethiodide is a tribasic
amine. The error resulted from mis-parsing the common
name at some point as meaning that the compound is a salt
of gallamine and ‘‘ethiodidic acid,’’ identifying gallamine
as the active component and retrieving the relevant struc-
ture. In fact, gallamine triethiodide is what you get when
you react gallamine with three equivalents of ethyl iodide
(Fig. 1).
It is easy for a name-to-structure conversion program to
make this mistake with a common name rather than ‘‘the’’
systematic one, but the ‘‘triethiodide’’ usage is systematic
in its own context. It is also arguably quite reasonable—
provided one already knows what gallamine is. The same is
true for stearates, acetates, palmitates, etc., where esters
often get mixed up with salts. When correctly used, such
names are correct and unambiguous in context: 4-andros-
tendiol has no basic centers to form a salt with acetic acid,
so ‘‘4-androstendiol diacetate’’ has to be an ester. The
problem is that the usage does not conform to the universal
standard expected by software that ignores chemical
context.
(As it happens, a simple Web search fails to make it clear
what the ‘‘correct’’ IUPAC name for gallamine triethiodide
actuallyis.Severalsites,includingWikipedia,[22]giveitas
‘‘2,20,200-[benzene-1,2,3-triyltris(oxy)]tris(N,N,N-triethyle-
thanaminium) triiodide,’’ whereas WolframAlpha gives it
as ‘‘2-[2,6-bis(2-triethylammonioethoxy)phenoxy]ethyl-tri-
ethyl-azanium triiodide’’[23]. The simpler ‘‘1,2,3-tris-
(2-triethylammonioethoxy)benzene tri-iodide’’ is more
informative and fully consistent with the example provided
as part of IUPAC Rule C-816.3 [24] but is unlikely to be
produced by any automated name generation program that
starts by searching for a base name using a prioritized look-
up table.)
The authorshave been particularly sensitized to this issue
bytimerecentlyspentcuratingadatasetofcytochromeP450
(CYP) reactions, where typographical errors and misinter-
pretation ofsemi-systematic drugmetabolite names were all
too common. Ironically, the use of such names in the liter-
ature (as opposed to fully systematic IUPAC nomenclature,
whichismorepronetointerpretiveandtypographicalerrors)
often makes it easier to determine the actual structure of
substrates and their metabolites. That said, it is the authors’
experience that there is no substitute for explicit structural
depiction in facilitating validation, something which should
be strongly encouraged in all publications, especially when
new compounds are introduced.
It is tempting to automate curation itself by accepting
the version of any given factoid that appears most fre-
quently on the Web as the correct one. The ease of
implementation seems to make the use of such methods
inevitable, but the potential for (false) positive reinforce-
ment in such a system may do more harm than good.
Indeed, the origin of the quote attributed to Niels Bohr at
the start of this article has been addressed in just this way—
a process which readily yields the wrong answer [25–27].
Mis-attribution of a quote is arguably inconsequential,
but misassignment of structures—either base structures (as
for gallamine triethiodide) or tautomeric and protonation
states—can severely compromise a model or simulation.
This is especially so when the error is systematic, as in the
case of steroid esters or ethiodide salts. The extensive use
of automated systems for populating public and private
databases with standardized structures can severely exac-
erbate the problem. Misprotonation examples include the
misrepresentation of piperazines as diprotonated rather
than as monoprotonated species and the conversion of
amidinium ions into diprotonated aminals (Fig. 2).
Such unlikely proximal dications are generated when
proximity effects—context—are ignored, and docking such
species into a binding site that bears a net negative charge
will wildly exaggerate the afﬁnity of the compound in most
cases.
Typographical and incidental analytical errors creep into
databases as well. So long as science progresses at least in
part by making constructive mistakes, there will always be
a considerable amount of bad data mixed in with the good.
Curating such large databases effectively is, however,
extraordinarily difﬁcult—and only rarely appreciated when
it does get done. The problem is exacerbated by three facts
of grant application life in 2011: that support is relatively
easy to obtain for compiling new cross-linked databases; Fig. 1 Conversion of gallamine to gallamine triethiodide
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the amount of data they include than on the reliability of
that data; and that it is very difﬁcult to obtain funding for
maintenance or manually supervised curation of existing
databases.
This is a remarkable state of affairs for a discipline still
recovering from the damage inﬂicted by the notion that
high-throughput screening and combinatorial chemistry
programs would produce a groundswell of new drugs by
sheer force of numbers. That experience showed clearly
that the quality of data is more critical than how much of it
there is and underscored the sharp differences in value
between data, information and knowledge. One hopes that
new compilations will soon be expected to provide an
indication of where each datum came from, if not the
ultimate primary source. The CYP curation effort alluded
to above was greatly facilitated by the data sets being well
documented in terms of citation of primary sources. It is
also important to cite the actual source from which data
was obtained, however. One often ﬁnds examples in the
literature (and even more often on web pages) where a
primary source C is cited, when, in fact, a secondary source
B was used which cited source C. Failing to acknowledge
such use of indirect data sources readily propagates errors,
e.g., when source B incorrectly copies or misinterprets the
information in source C.
Conclusion
When Garland Marshall, Andy Vinter and Hans-Dieter
Ho ¨ltje launched this Journal 25 years ago, it was believed
by some in the community that computers would ulti-
mately—perhaps sooner rather than later—displace human
beings from the drug discovery process entirely. Given that
fact, they might well have named it the ‘‘Journal of Com-
putational Molecular Design.’’ They opted instead for the
‘‘Journal of Computer-Aided Molecular Design,’’ which
proved a prescient choice. It is easier now to appreciate the
inherent limitations of computer programs as well as their
potential for augmenting and extending the reach of
molecular designers. The three hurdles highlighted here—
understanding entropy, estimating uncertainty and effective
curation of large databases—are daunting but not techni-
cally insurmountable. But the psychological and institu-
tional challenges they represent are perhaps equally
forbidding: people naturally tend to focus on the direct and
familiar (enthalpy) rather than on the subtle (entropy); they
resist quantifying how much they do not know (uncer-
tainty); and they tend to favor increasing quantity at the
expense of quality (curation). Those aspects of the chal-
lenges, too, can be overcome. If the community does so,
the fruit of our labors will be evident to our successors
25 years from now when they read the Journal of Com-
puter-Aided Molecular Design as their cars cruise through
the air on autopilot. Or perhaps they will prefer to hear it
spoken directly into their minds through their brain chip
implant as they try out the latest jet-pack.
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